EZH2 and pancreatic neoplasm: Moreover, a subset of patient-derived organoids displayed sensitivity toward EZH2 inhibition [84], suggesting the potential of EZH2 blockage for pancreatic cancer treatment, possibly in a model of personalized medicine based on an organoid platform.